|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 4 (August 15), 1999:
pp. 1382-1392
CD22 Cross-Linking Generates B-Cell Antigen Receptor-Independent
Signals That Activate the JNK/SAPK Signaling Cascade
Joseph M. Tuscano,
Agostino Riva,
Salvador N. Toscano,
Thomas F. Tedder, and
John H. Kehrl
From the Department of Medicine, UC Davis Cancer Center, University
of California, Davis, Sacramento, CA; and the Department of Immunology,
Duke University Medical Center, Durham, NC.
CD22 is a B-cell-specific adhesion molecule that modulates
BCR-mediated signal transduction. Ligation of human CD22 with
monoclonal antibodies (MoAbs) that block the ligand binding site
triggers rapid tyrosine phosphorylation of CD22 and primary B-cell
proliferation. Because extracellular signal-regulated kinases (ERKs)
couple upstream signaling pathways to gene activation and are activated
by B-cell antigen receptor (BCR) signaling, we examined whether CD22
ligation also activated ERKs and/or modified BCR-induced ERK
activation. Ligation of CD22 on either primary B cells or B-cell lines
failed to significantly activate the mitogen activated protein kinase (MAPK) ERK-2, but did activate the stress-activated protein kinases (SAPKs; c-jun NH2-terminal kinases or JNKs). In contrast, BCR ligation
resulted in ERK-2 activation without significant SAPK activation.
Concurrent ligation of CD22 and BCR enhanced BCR-mediated ERK-2
activation without appreciably modulating CD22-induced SAPK activation.
Consistent with its induction of SAPK activity, there was a marked
increase in nuclear extracts of activator protein-1 (AP-1) and c-jun
levels within 2 hours of exposure of primary B cells to the CD22 MoAb.
Despite their differences in ERK activation, both CD22 and BCR ligation
triggered several Burkitt lymphoma cell lines to undergo apoptosis, and
the 2 stimuli together induced greater cell death than either signal
alone. The pro-apoptotic effects were CD22-blocking MoAb-specific and
dose-dependent. Examination of expression levels of Bcl-2 protoncogene
family members (Bcl-2, Bcl-xL, Mcl-1, and Bax) showed a
downregulation of Bcl-xL and Mcl-1 after CD22 ligation.
This study provides a plausible mechanism to explain how CD22 and BCR
signaling can costimulate B-cell proliferation and induce apoptosis in
Burkitt lymphoma cell lines.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Santos, K. E. Draves, M. Boton, P. K. Grewal, J. D. Marth, and E. A. Clark
Dendritic Cell-Dependent Inhibition of B Cell Proliferation Requires CD22
J. Immunol.,
April 1, 2008;
180(7):
4561 - 4569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Haas, S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder
CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo.
J. Immunol.,
September 1, 2006;
177(5):
3063 - 3073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zhao, S. Maruo, A. Cooper, M. R. Chase, E. Johannsen, E. Kieff, and E. Cahir-McFarland
RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines
PNAS,
February 7, 2006;
103(6):
1900 - 1905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dunussi-Joannopoulos, G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H.-L. Ma, P. R. Hamann, et al.
B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model
Blood,
October 1, 2005;
106(7):
2235 - 2243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. X. Xing, X. F. Hu, G. A. Pietersz, H. L. Hosick, and I. F. C. McKenzie
Cripto: A Novel Target for Antibody-Based Cancer Immunotherapy
Cancer Res.,
June 1, 2004;
64(11):
4018 - 4023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg
Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
April 15, 2004;
10(8):
2868 - 2878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Poe, K. M. Haas, J. Uchida, Y. Lee, M. Fujimoto, and T. F. Tedder
Severely Impaired B Lymphocyte Proliferation, Survival, and Induction of the c-Myc:Cullin 1 Ubiquitin Ligase Pathway Resulting from CD22 Deficiency on the C57BL/6 Genetic Background
J. Immunol.,
February 15, 2004;
172(4):
2100 - 2110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al.
Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties
Clin. Cancer Res.,
September 1, 2003;
9(10):
3982S - 3990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, et al.
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
August 15, 2003;
21(16):
3051 - 3059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J.S. Dyer
Bioweapons of Tumor Mass Destruction?
J. Clin. Oncol.,
August 15, 2003;
21(16):
3011 - 3012.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Tuscano, R. T. O'Donnell, L. A. Miers, L. A. Kroger, D. L. Kukis, K. R. Lamborn, T. F. Tedder, and G. L. DeNardo
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Blood,
May 1, 2003;
101(9):
3641 - 3647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. John, B. R. Herrin, C. Raman, Y.-n. Wang, K. R. Bobbitt, B. A. Brody, and L. B. Justement
The B Cell Coreceptor CD22 Associates with AP50, a Clathrin-Coated Pit Adapter Protein, Via Tyrosine-Dependent Interaction
J. Immunol.,
April 1, 2003;
170(7):
3534 - 3543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Otipoby, K. E. Draves, and E. A. Clark
CD22 Regulates B Cell Receptor-mediated Signals via Two Domains That Independently Recruit Grb2 and SHP-1
J. Biol. Chem.,
November 16, 2001;
276(47):
44315 - 44322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara
Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways
Cancer Res.,
December 1, 2000;
60(24):
7170 - 7176.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. C. M. Brinkman-Van der Linden, E. R. Sjoberg, L. R. Juneja, P. R. Crocker, N. Varki, and A. Varki
Loss of N-Glycolylneuraminic Acid in Human Evolution. IMPLICATIONS FOR SIALIC ACID RECOGNITION BY SIGLECS
J. Biol. Chem.,
March 17, 2000;
275(12):
8633 - 8640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Poe, M. Fujimoto, P. J. Jansen, A. S. Miller, and T. F. Tedder
CD22 Forms a Quaternary Complex with SHIP, Grb2, and Shc. A PATHWAY FOR REGULATION OF B LYMPHOCYTE ANTIGEN RECEPTOR-INDUCED CALCIUM FLUX
J. Biol. Chem.,
June 2, 2000;
275(23):
17420 - 17427.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
